Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics First Quarter 2023 Results Conference Call.

Before we begin, we want to advise you that over the course of the call and question-and-answer session, forward-looking statements will be made regarding events, trends, business prospects and financial performance, which may affect Plus Therapeutics' future operating results and financial position.

All such statements are subject to risks and uncertainties, including the risks and uncertainties described under the Risk Factors section included in Plus Therapeutics' annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission from time-to-time.

Plus Therapeutics advises you to review these risk factors in considering such statements. responsibility events, or the trends are no statements any date assumes made. reflect to or Therapeutics to revise update forward-looking they Plus circumstances after

Dr. turn now Executive Chief you floor pleasure is Sir, Plus to begin. It over President my Officer. to Marc may and Hedrick, Therapeutics' the

Marc Hedrick

quarter and our Good recent results. we again provide financial overview you of for XXXX us taking you, Jonathan. thank join as Thank the highlights today discuss and business first afternoon, everyone, once time to an

Joining Chief me is call Andrew LaFrance for to joining Norman I'll the for on clinical the call Dr. financials. focus first then our and will review the be the recent the LaFrance, today turn Officer, call Medical quarter, and over Andrew our with then Q&A. us Dr. regulatory by begin Financial to Chief reviewing our Sims, progress our Officer. and

endpoint response, such XX-centimeter of response objective and overall sized dose number off. primary such or highlighted The MLs. survival enrollment partial Phase programs Phase in medium can is small we Starting trial X.X to a a we had a clinical very or single and endpoints the six are Metastases typical XX.X GBM or two with actively enrolling tumors lead to is PFS are with months. XX obisbemeda as GBM start the trial, Xb productive of our LM. our rate, a increased patients program by And XXXX in administered cc there XX Rhenium and Leptomeningeal of and I Xb with the milliliter cut GBM glioblastoma the secondary say millicuries at safety, and momentum

The XXXX Phase patients for XX Institute is to to the sites. trial at Cancer at five to is that. present substantially and do goal patients by Xb end by of National funded on are schedule the we of complete up Our enrollment XX

expand presumed and to rapidly to number the trial process Xb negotiating pivotal a we the X We are the of sufficient, a trial such Phase with NIH Phase in can the thereafter. that sites complete

to sites, are over discussions the we parallel are trial the XX as new and our trial. In see the engaged in NIH, with U.S. we actively and sites possible interest pleased that with with Europe in we

the more dose X regarding tumors Now ongoing GBM trial escalation larger Phase ccs. XX for and over complex

in now the patients escalation required are and As a in enrolled That volume dose in used dose administered have current volume double and announced, approximately millicuries Phase dose Xb. cohort and XX.X we three dose the of X milliliters. XX.X the

since have how been escalation the In to tolerated XX we initiation, point have based trial. total trial patients enrolled yet proceed. Since the of in options we several have dose of terms a X Phase we may trial dose, stopping a just Phase on reaching reach in maximum portion X

and We steps from intend eight seven is and formulated. data from are analyzed the the next in on once is and process of the X provide cohort guidance analyzing to a the Phase plan data

portion escalation trial. notes new breaking Now we on of whatever in do terms this that Irrespective we a here the ground want or highlight I with medicine in a are dose steps, X the of bit perspective side to of trial. this fact Phase of next

a we may cerebral it's a Specifically, XX more, XXX we've gray tolerated including or administering of patient able administered if safely now you the lost in to up maximum that the to want we Don't that dose. look to to volume haven't remarkable that delivering do be a in tumor. have dose and administration are single to hemisphere, safely that radiation reached been that tumor here in terms a amount single of of and truly a ccs

development LM the So to moving on program.

and X ReSPECT was Phase protocol. As have of announced, under in maximum up retreated we one the millicuries treated X.X In The and three cohort three were Cohort Cohort that in compassionate LM completed total dose in is the X. delivered cohorts fact, thus CSF the been XXX administered patient At dosing gray is maximum far, was trial. far, the approximately from dose patients X that XX.X use X across administered A computed millicuries Part in dose, thus to radiation. absorbed

be to profile followed X negotiations dose requested have no the FDA under a already trial. LM able nine of us with Phase through our the separate been an X the over is It's meeting doses treated is Cohort of is dose a safety to continue B Presumably thus dosing until helpful trial toxicities conduct appears forward far, The Thus our as time then multiple remain far to as FDA reached, for and treated be original the will and we C two during XX the finalize treatments. administration to for Part use dose meeting, maximum DSMB thereafter. one by has to plan patients a compassionate to observed GBM favorable. in by alive. to go escalate limiting the patient regimen In incorporate tolerated Type single

and develops. Separately, institution specifically a we're more leptomeningeal on about working metastases that for single that primaries, trial melanoma as

we until to patients follow and physician trial approved. feel to retreating selectively data addition, up period XX Difficulty]. the additional cohort In the be days is as consider and treat patient it plan efficacy cohort gain stipulated with I their dose of And will patients if X [Technical X mentioned would after safety we

trial XX onboarding and are As sites with B, currently the under sites GBM for Phase trials, the heavily XXXX evaluation. we LM are focused in part X new

CPRIT for support last through grant awarded the receive to continues year. our Plus $XX.X program Finally, million

brain high-grade rhenium Based efficacy for pediatric updated application what ReSPECT and pediatric specifically PBC be development obisbemeda expect thus of FDA, glioma. to brain new a finding two had submit safety Phase study regarding almost the for year, back-and-forth soon Now dose with back tumors, an program cancer. drug will our we've goes the called which at for ependymoma X communication and on investigational the far we

will additional The together FDA trial trial, as has data essentially asked be and the the conjunction in University of will they've update. way put with safety along academic for from this and but Chicago. submitted that working on with in Hospital be been we've human signed part the refiling lead off that's the clinical on IND Northwestern which that trial institution we've That Children's of plan, Lurie

available chain. chain, about clinically to relates the for stage as bit it's that appropriate have development and Now patient are to a we're any we at in drug that we it important treat we where very supply our supply a

chain anticipate for rhenium obisbemeda redundant critical. is supply suppliers impact So We added in supply potential have and key as or Phase quarters, and approval an we X In accelerated in tract, relationships previous trials. an a developed to trial, maintaining and new for our drug CMO those a XXXX fact add such GMP relationships we that have expand for ready presents continuing alternatively that itself. if robust are consummate relationships we

bit in about planning and relevant consistent coding proceeding stage economic including of development. commercial a launch pricing planning, are ultimately, decisions commercial go-to-market planning, considerations the drug background Now commercial with medical our and and research, billing

technology BAM, kidney feasibility perfusion work microparticle completed ex we license regarding radio the closed Now the vivo a embolic RNL that product, technology, licensed in human the transferred in product BAM. model. manufactured in RNL for our novel Recall successfully XXXX, and

on previously end at regulatory XXXX. the an the also a designation. FDA, FDAs designation We sought dialogue the active Currently, request preliminary have ongoing opinion for of with we including submitted

device, legacy and but outcome for next years, that program, in timeline product, we the this The of await clinic, many the as or the that drug the XX preclinical outcome development that of the back-and-forth. is the of notably a we been that drug, steps determination have specifically, combination likely whether will products out think our designation dictate a to regulated be should plus devices, ultimate

program, development summary, Financial our with the on over who financials. Andrew the floor to So Officer, Chief that review I'll turn our will Sims, Andrew? clinical

Andrew Sims

you, Please the results of issued ended everyone. summary today, our a quarter March release Thank XX, our Good Mark. press for refer earlier financial XXXX. to first XXXX for afternoon,

were million, cash XXXX, and of compared XX, XX.X cash XXXX. to As of XX, as million equivalents March December XX.X

addition million its NIH million. X from benefits discretionary, at to In company least has access also hand, on million from grant credit equity line current XX XX.X approved ATM The the company and from capital CPRIT. to the stockholder cash and of from or awards of of

XXXX, In capital same fully currently costs incurred to XXXX provide XXXX to these total million a for for expenses to our year. the X.X period Total compared first program. fund utilized. prior operating LM The CPRIT million, capital X.X of of operating of the portion represents grant aggregate can of share of of the XXX,XXX quarter which expenses activities were clinical sources anticipated the fund sufficient quarter planned first through recognized revenue in company and

licensed and related successfully primarily Corp enrollment payment milestone XXX,XXX nano programs. to clinical due development to lead meeting due is increased the increase company's expenses The to TX clinical a in a key for

XXX,XXX, Interest November the expense in the decreased Oxford million or $X.XX to the Net loss per for X.X share, first a period or prior. million, quarter XXXX. that XXXX XXXX XXX,XXX company's to for down the quarter XXXX decrease reflects of $X.XX was per for of loss principle the quarter the continued compared X.X first debt. the This first net quarter the for of of same commenced from pay on share

Marc. turn will it I Now to back

Marc Hedrick

Andrew. you, Thank

anticipated on milestones move the allow me we Q&A, on for remainder to of provide guidance Before XXXX. to

respect Importantly, journal. we a the publish to GBM peer Phase intend data reviewed in X

as from X trial to and of second half part well as of trials Second, efficacy the leptomeningeal as in present the we of of second respect the data Phase safety the data in XXXX XXXX safety and efficacy the well. present GBM intend metastases half respect A

LM meeting site part trial, complete activities, an ReSPECT year that second full the we meet Xb We Type key anticipated enrollment We GBM the can Phase the FDA expansion XXXX, as B mid-year. mentioned following Phase trial such and end of XXXX. initiate by enrollment intend in to C ReSPECT also in half intend trial of X to

ReSPECT trial initiate appropriate intend regulatory designation the determine pediatric trial RNL activities the brain technology key pediatric glioma. or ependymoma as FDA PBC patients cancer the to BAM for development We X with for high-grade plan and mentioned. complete We to to Phase

secure applications to along non-dilutive development drug support for and pipeline. to GBM we LM. studies of therapies to additional grant expansion order capital drug with submit to multiple obisbemeda, intend rhenium preclinical of And systemic to intend also try company's the We complete synergistic in combination

over you, Jonathan. point, go our it So at me now, let to turn through Q&A this back session. We'll

Operator

understand we'll that those from Trading I Jones some take [Operator And and Instructions] from we questions questions Justin also Walsh that have were first. pre-submitted

Andrew Sims

Thanks, Jonathan.

remind in and imaging the therapy for in Justin, the and you and/or benefits can to of that, to the thank up versus approach the development want your Norman is cancer? be cancer. follow a landscape for first evolving the molecularly potential in commercial us systemic radiopharmaceuticals targeted comments brain as seems the spotlight emailing And cancer? radiopharmaceuticals success approaches if prostate notable on And brain questions. to. question in of of context you you Any with

Norman LaFrance

you. Justin. Thank for Yes. that Thanks question,

typical gets and us it platform. distinguishes what doing to we're de-risks think our on our I core this of particularly radiopharmaceuticals. delivery But of based the what very efforts

was the Your kind having first of success. Difficulty] commercial question [Technical

they're products, and the an serotonin products well and need. filled welcome and medical the important So were lutetium PSMA, aware of,

and language But is of targeted and these the use the and the in product and good in to extra as tumors, yttrium-XX. where both had that. money that risk are both lutetium preclinical the was technology, neuroendocrine those fine goes doses common these profile. what's Again, insert to safety classic Both I think accomplish then radiopharmaceuticals, the DOTATATE they're similar and administered starting developed of was the There that and I'll very both for the but recognized some clinical the confirm efficacious and with toxicity. systemically trials was representatives package the clinical time excellent DOTATOC serotonin the requirement along trials And mid-XXXXs. you there targeting renal it optimize of that Lutera product. the for during both have a products, had were required development

successfully know time that of I the enhance So with, at renal dealing the of and the that administration product. [indiscernible] time spend that the excretion in to think with did to community accelerate goes the had folks they

kidneys, the to you to to best get targeted be therapy. benefits So decrease absorbed able the unnecessary dose the and

we're me that doing. So to what gets

we It's radiation accepted the non-controversial. That's common approach works well all So is, in for very know cancer. been decades. well the one,

it's established CD well the Difficulty] What in lesion get when right we're use I'll it's discovery well-established extensively where system whole late access used been so and convection [Technical XXs, and is early the leveraging elegant with and appropriate the brain first and by in by barrier needed, central have nervous a forth catheters, blood delivery in an XXXXs to and GBM NIH catheters, enhanced administrations needed. that the the chemotherapy, the challenges,

get that didn't there and doing, result effectively Well, but Phase these in away despite one, in promising did unfortunately, diffused preliminary some the technology, improvement with patients very studies. were promise significant also initial these any molecules typically excellent quickly and delivery early, how

people But those those because local that and is why for for delivery chelated think accepted rhenium reviewed the have XXX. folks X and molecules in chelated Bifunctionally publishing at direct that submitting of at that I it sadly, optimal because durable been And the the have the the I to for Marc rhenium presentations, recognized details delivering And mentioned, bifunctional as an a peer won't we're tumor. choice publication. delivery, they've and after is isotope. end radiation formulation for go coming the or of chemotherapy, seen with which going regional way however, meetings. Phase day, Holy Because behave now And be was not weeks a encapsulated to localization therapy the realized. nearly isotope, of [indiscernible] Grail -- of into our data our locally, the

So we're go. to providing where is stay the the it the get to the physical through case what there. isotope able to there cycles, which differentiation needs efficacy And it center allows successfully formulation half-life our to is, is,

systemic radiopharmaceuticals suffer challenges so the They established of the some on blood and out very works same chemotherapies barrier, the what, other challenges it And that question maybe therapies. your touched So systemic brain well. forth.

direct accomplishes. intra your metastases Hopefully subarachnoid the leptomeningeal Ommaya Justin. way delivery Thanks. the local both to same that comparable we're that's paradigm and accomplishes neurosurgeons and and oncologist catheter, GBM to And the in that an delivery ventricular our via So satisfies by told paradigm and a an direct go. way, the that space reservoir the delivery administration question,

Andrew Sims

pharmacy? question. commercial addition sites with a it have down any only the new of a to great any be that of to a you working And how could to see sites? challenging sense do And as trial assets success translate imagine of at you potential top provide e.g. administered or then could hospital line? Second do It's what Memorial these color is the how type on Hospital versus Can radio Norman? centers Northwestern site. onboard you easy

Norman LaFrance

too. that take I'll

I'd sign Some easier at very points straightforward. getting on use I'd good is But very the board like touch, a to this. I smile your challenging rather on for word, sites.

that cooperate have major coordinate protocol various like how oncology, and scope events and nicely a We patients treated. events nuclear the neurosurgery have three well-defined documents, and we a have that, things of the medicine neuro collaborators, the sequence have collaborate, in mesh in to manner, to well-defined get to and the

in protocols involved. Northwestern very We're processes at defined a well our that's all So our site. to proud involve and

processes contractual that pipeline is thorough the in do in others get manner. of process of to the are have are that number board. there. them established plenty on to we that very time a a And effective, have well We such And the

in that the mentioned, a involved neurosurgery, oncology, fact three activities them do. that that processes say medicine, all things and I points and major the just But do have are I have patient, and of with give and home and for of, nuclear time. call we get that the particular it virtual neuro are found -- the our out sites sites well-defined typically We to of they evolving the like work they're issues we I each COVID coming that areas staffing collaborating particular folks doing era this. at all process that how

very sites, the other, terms going we've the they at would inquiries data, sites of on. see what's Because data, In you getting the elite the expect. are of lot see from that a that these and We're each to pleased been talk sites. they hear the meetings, tolerability actually we're they they safety presenting of

commercial of platform. So data they're success itself, be for core coming have let the any along. of course, future we the speak there'll And

present large on, want goes commercial non-elite time even, and as sites, inquiries call to them don't from hospitals. as data, we're I the and interest getting But we more but

imaging radio radio is and to administer. an that Most for use the they used the sites have to mentioned pharmacy, You ready prior local pharmacy and do not site patient to shipped the in have, have product active you to doses both large pharmacies decades, ready therapy. deliver

we for be the and the XX by sites whatsoever. pivotal XX to have the not issue sites more. be then will, find an And sites that launch, to platform in using we will we're or a commercial that will expect trial, So

think last all that I question. covers Thanks. this hopefully, that in you So asked

Andrew Sims

Questions, color what half in estimates from numbers, cetera. additional any patient three. readouts For we on of Can should you second data on provide the the example, XXXX? expect et

Marc Hedrick

take that. I'll That's okay.

So, yes, reiterating. kind of

the mentioned I of be X publication a one been data evaluation comprehensive six, by the peer get published, with is, to top will cohorts earlier, tier, the reviewed Phase through full a we've a, what that for Justin, high to submit. that's And journal, plan GBM invited factor impact data. statistical

done. So that's largely

to also, will and hopefully, new board, in get that go reviewed use because with data sites So Norman discussions will said, that's we that be can And peer helpful that on well. sites. as

Part X well the to presentation there Phase GBM, plan present podium A trial LM. be as most Phase Neuro trial, for X to as the the In well the terms both likely oncology the X, plan the X, for meetings. had with the We as there present Phase well of a as of half second And coinciding, as ongoing be and Phase would would X, present from Society last data update November. and GBM, LM year,

question was of enrollment. And I the the think estimate second part

not this patient, hypertensive plan XXXX our trial. is a what any I So mean,

here enrolled better a Our if ahead not, schedule, we've something calls materially or plan to place timeline of we'll mention it's example, to to, us we're XXXX, of a perhaps on X, in for or on worse, by get is happens, schedule bit in got that. quarterly guidance end the to Phase whether provide we'll

However, my the in of data patient preference numbers, itself. the is not to specific present absence

we'll And milestone when individual that terms a that, to of we not numbers, terms earnings so, enrollment, announce we'll present in of in or discuss our trial patient no but it's numbers. hit major for update call example, on or

LM the practice, to relates or that it be regulatory enrollment when those. present each As as we'll present But hit we'll will major milestones we cohort is we current to milestone. our which trial, likely continue more milestones, hit frequent, announce

So that's the will plan update accordingly. and we folks

Andrew Sims

from Justin. Based with your patient question that pace obviously on enrollment. keeping you've on comment updates, you encountered? investigator Can and you're Last enthusiasm

Norman LaFrance

expand enrollment Marc as I the see. in is sure do the of and to within sites what we But Phase that our for soundtrack, the we hear the has mentioned, sites. it's appreciate. have be think getting the on we on of plans what to enrollment, call And making sites depending feedback. a nice number that's might all X scope the Justin, those agency rapidity always going had will about mentioned also from we how FDA of Marc we, It's everyone and to perform well,

oncologist, now And Lifetime the a have past the got think, his And that -- the saw get this, involved in respect Hopkins that. ask you And really of of patient know and to have on lot for colleague And meeting, recent there. emphasize recognized. and and investigator I And way example, folks got enthusiasm in ask by I the Grossman paraphrase got I of from liked quick And, Skip cut about we're maybe you that's to both investigators, LM. I'll each respected examples. we field and folks have a person heritage, the couple comment, Award. one we're motivated others SNO neuro patients and get there and LM our other, give and one really I he Achievement I nothing. and is had something the I getting important it's very this both, know at trial. consistently think and sites I to well-known the you and a What speaking these think mine, of of we the and presentation is, we And

I'm other is, some it other up, that once communicating it, opportunity, grateful I it realize in in experienced, ways. than this asks names gone go just peer have that have And they've review and plea for I I I we've about of observer. to this it's how and no Or I this both a acceptable. difficult in site. for observation presented. have to you are and the option, some that's for different it perspective, there and And was follow and asked patient more one, that just newer can Marc to And we've similar there important gotten patients presented what a the and we to options. my I said, institutions second that I've maybe an sometimes we've sites, done. give can be a it's particularly heard put through what eyes data didn't and Equally other in this of And many the set participate I they've ears the way, some site have But patients easy. involvement is is feel patients, way an when a --

who I I'm simultaneous typical things, And had other walking, and won't Marc a on about drop give on example, GBM patient, and detail. you your out having on had into patient, And that weeks his evaluation his a to now asked treatment, go he going He he GBM think lamented embarrass of specific site three to the everyone complications, the I of difficulty back a short, him his real-time as softball. have about was to two To after because we treatment, senior of playing to me softball story and so send league knows, forth. make within because long to gamer. pictures

the treatment able to very where accurately we're goes. So validate

is be website, to his his case, a to make that. know he to of kind folks wanted has short, that who way think he that. running and be success again He to doing story Xk, was be can So my in question challenge, able of I Xk the he running raised there is, process month. him. things share has. next the esteemed And of part own commenting story this I he our about, Chief Executive we're will And of story, in Officer with the this a And that and sharing patient's gentleman will the have long

sorry, will of So been embarrass is and a to both investigators Marc, example I'm it you. product But me has but I figured only enthusiasm prime for this very not patient the for personally this professionally. really how gratifying

you, for Justin, thank So that.

Marc Hedrick

Jonathan. Okay,

got Justin questions. his think those worth money's I on

next? have we do who So

Operator

Certainly. from Wainwright. Then line HC from of phone our first Sean Lee the line comes question the from

please. question Your

Sean Lee

potential GBM for is mentioned you doses something treating your would two I larger on the that Phase roll separate, of higher it's consider regular to higher first side. and will future the the into the you wondering been going whether dose test study able was GBM, X My well, tumors know question you keep has you I RN. that the and in be dose? or like

Marc Hedrick

on depends data. It the

I three as first X. probably know, the volume you I'm the radiation. patients three And in effect we to cohort you of An do cohort sure Sean important the back second flow six, from distribution, as X patients in the at actually cohort think increasing that part analyzing -- rate think, we're the X. increased is process I mentioned, in and of I looking and the of

of there's of to and We're wants, lot think delivery gone value before the and we there I pull. anything So And putting we're no in do to I this would And at terms what the out parameters. man NCI kind in is can wouldn't going where patients continuing wants. volume, has real are FDA the levers rule of amount tweaking that's to But the brain, do just point. that. and that's of what we radiation, plan our say continue finish. a

Sean Lee

My study. is thoughts second question your for that. on Thanks see. LM I the on

you You particular melanoma if in you suited mentioned [ph]? you and one other something melanoma see to that you testing treatment] patients, cases, looking with it for well makes why were particularly in or way that's is think, there's that [end

Norman LaFrance

another that many Because even I tumor, caused of from and me the Let question. LM, the phone brings liquid primary on -- take which it And aspect the -- can we up tumors any know, solid brain think of appreciate that folks tumors. any one. I be

most be lung, course, head, a indication. frequent. by much melanoma they've typically require breast, I disease prevalent, will the neck, Of specific GI, Regulatory and this are and call FDA what most requirements said

help. target and with etiologies to So would disease people we given But us the it LM, will likely that on breast, comers. all would have focus, have most although and regulatorily, current with for going can focus escalation, we do that the our is it the specific way forward, pick most ones written I our the lung that see our in protocol dose initial we

a checkpoints and product, for indication. is go determining a with select now. approach And real approach therapeutic in there's And example more with in inhibitors and particular. therapies combination Melanoma with I our combination melanoma for of the has or that now a systemic treatment difficult But checkpoint general disease a we're another lines. splitting into particularly some opportunity systemic in an that immunotherapy way we're complication. because it's out But the other won't with a leptomeningeal some is reason whether immunotherapy shown effects,

Sean Lee

adults? to make adjustments it just than to you. with your I wondering going study, be different to question what had pediatric you uses know on any delivery far specific final you've was the the upcoming catheters, very helpful. so Thank whether Because is That is method? done My the connection

Norman LaFrance

no, answers. little known bit question. great more Yes, for And me one-word let short the a I'm my is, but give color. answer not

pediatric the are the So be [Technical Difficulty] And It'll neurologist used about epileptic approach. and is for is evaluations. sorry interesting to that. same what

adults, three but a You doing this two child's be four used X, more brain would with oh, catheters, they're XX catheters. putting X, or as to to Well, or only my catheter goodness, with we're or not tough. think, in doing a is going

the tracing, CD with, So all they something the and do epilepsy targeting and catheter is electrode very comfortable they're time, example. retrace, approach for

the that particularly these be we for And differently. volumes, cohort that be going something anticipate quite some be we'll to only volumes. already mentioned that can X, dose have evaluate to I the thing the Marc escalations of increasing we're get ependymoma, for later larger different will as into maybe would might in is be volumes. those large And adult

greater times, we that using of see anticipate of although same So even will the the that by catheters tumors, volumes be think of the the I reducing can means would reduction unit And given volume mentioned infused larger and kids. in adult that very fact more infusion dose tolerable and we're I depending a which reduction have administration, the be and And over likely in catheters I the occurs larger fixed I that in course, for already time. possibilities XX%. on X, more

question, does answer Sean? So your that

Sean Lee

Thank does. again questions. for you it Yes, my taking

Operator

you. line Woo next Thank Capital. of One comes our Edward the from question Ascendiant moment And question. for next of our

please. question, Your

Edward Woo

requirements running your trials? have question all there on the the look on congratulations Are that where progress. can any to or restrictions when any you're My sites these guys other clinical grant. is Yes, you at CPRIT you

Marc Hedrick

in to terms where those employees forth sites on and restrictions some Texas, in so so having forth, having Texas be. sites in no sites. restrictions but of There's around spaces can and clinical There’re office not and

Norman LaFrance

restrictions. [bet We can on] [ph]

Edward Woo

have. you. Thank that's the questions Well, I all Great.

Operator

you. Instructions]. Dr. further session this I'd to the remarks. Marc [Operator conclude to Hedrick back any program. program like the hand for And Thank today's of question-and-answer does

Marc Hedrick

finish physicians Thank a stockholders and questions wish up Appreciate employees our you, today. you with you for we collaborators support. questions and attention. work appreciate your And the our their Jonathan. continued we want for evening. thanking and and we today And Thank to patients nice Thank you. and the by have

Operator

ladies Thank you, and today's This your gentlemen, conference. in conclude the program. for does participation

You day. disconnect. Good now may

Marc Hedrick	President and Chief Executive Officer
Norman LaFrance	Chief Medical Officer
Andrew Sims	Chief Financial Officer
Justin Walsh	Jones Trading
Sean Lee	HC Wainwright
Edward Woo	Ascendiant Capital

Plus Therapeutics (PSTV) 20 Apr 232023 Q1 Earnings call transcript